Most big pharmaceutical companies struggle to keep one megablockbuster drug in their product lineup. Recently revealed results from an Alzheimer's disease trial suggest that Eli Lilly (NYSE: LLY) could be poised to reap huge gains from not one but two of the world's most valuable new drugs.

We're not the first investors to recognize the potential in Lilly's pipeline. The stock is up 69% since the beginning of March.

Let's weigh the company's recent successes against the challenges it faces to see if buying the stock is a smart move right now.

Continue reading

Source Fool.com